Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

• Status: Recruiting
• Trial end date: 2024-12-24

Summary

This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly diagnosed multiple myeloma.

• Phase: Phase 3

Details

• Lead Sponsor: University of Chicago
• Treatments: BB 1101; Bortezomib; Dexamethasone; Dexamethasone acetate; Lenalidomide; Thalidomide